Unknown bone-metastasis-associated target

The term "Unknown bone-metastasis-associated target" does not refer to a single canonical molecule or receptor but is a generic description for various proteins and pathways involved in the colonization of bone by metastatic cancer cells. Bone metastasis is a complex process involving a "vicious cycle" of interaction between tumor cells and the bone microenvironment, where tumor-secreted factors stimulate bone resorption, which in turn releases growth factors that promote tumor growth. Key established targets in this process include the Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), which is targeted by denosumab to inhibit osteoclast activity, and various growth factor receptors like TGF-beta and CXCR4. Recent research has also identified novel or previously unknown targets such as the orphan G protein-coupled receptor GPR160, which is implicated in bone cancer pain and prostate cancer progression, and DACT1, which regulates Wnt signaling in bone-metastatic niches. Because the input name is generic and lacks a specific molecular identity, it is classified as an incorrect or incomplete target entry for structured pharmacological databases.

Other names

Bone metastasis-associated targetSkeletal metastasis-associated targetBone-targeting moleculeMetastatic bone disease target